{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:17:42Z","timestamp":1790720262701,"version":"4.1.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T00:00:00Z","timestamp":1710115200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.schres.2024.02.035","type":"journal-article","created":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T09:07:32Z","timestamp":1710580052000},"page":"193-204","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Response rates to sequential trials of antipsychotic medications according to algorithms or treatment guidelines in psychotic disorders. A systematic review and meta-analysis"],"prefix":"10.1016","volume":"268","author":[{"given":"Brian","family":"O'Donoghue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Piacenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Plapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Siskind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Lyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.schres.2024.02.035_bb0005","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.4088\/JCP.09m05785yel","article-title":"An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis","volume":"72","author":"Agid","year":"2011","journal-title":"J. Clin. Psychiatry"},{"issue":"11","key":"10.1016\/j.schres.2024.02.035_bb0010","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.4088\/JCP.09m05785yel","article-title":"An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis","volume":"72","author":"Agid","year":"2011","journal-title":"J. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2024.02.035_bb0015","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/acps.12327","article-title":"The practical management of refractory schizophrenia \u2013 the Maudsley treatment REview and assessment team service approach","volume":"130","author":"Beck","year":"2014","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2024.02.035_bb0020","first-page":"1","article-title":"Association between previous and future antipsychotic adherence in patients initiating clozapine: real-world observational study","author":"Brodeur","year":"2022","journal-title":"Brit. J. Psychiat."},{"issue":"6","key":"10.1016\/j.schres.2024.02.035_bb0025","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1192\/bjp.2022.47","article-title":"Real-world clinical and cost-effectiveness of community clozapine initiation: mirror cohort study","volume":"221","author":"Butler","year":"2022","journal-title":"Brit. J. Psychiat."},{"issue":"2","key":"10.1016\/j.schres.2024.02.035_bb0030","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1198\/sbr.2011.10013","article-title":"Time to all-cause treatment discontinuation as the primary outcome in the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia study","volume":"3","author":"Davis","year":"2011","journal-title":"Stat. Biopharma. Res."},{"issue":"3","key":"10.1016\/j.schres.2024.02.035_bb0035","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/JCP.0000000000001678","article-title":"Escaping the long shadow cast by agranulocytosis: reflections on clozapine pharmacovigilance focused on the United Kingdom","volume":"43","author":"de Leon","year":"2023","journal-title":"J. Clin. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.schres.2024.02.035_bb0040","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1097\/JCP.0000000000001303","article-title":"One-year outcome and adherence to pharmacological guidelines in first-episode schizophrenia: results from a consecutive cohort study","volume":"40","author":"Drosos","year":"2020","journal-title":"J. Clin. Psychopharmacol."},{"issue":"9","key":"10.1016\/j.schres.2024.02.035_bb0045","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1176\/appi.ps.53.9.1067","article-title":"Rehab rounds: a service response to prolonged recovery in early psychosis","volume":"53","author":"Edwards","year":"2002","journal-title":"Psychiatr. Serv."},{"issue":"2","key":"10.1016\/j.schres.2024.02.035_bb0050","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S2215-0366(23)00366-8","article-title":"Efficacy and effectiveness of antipsychotics in schizophrenia: network meta-analyses combining evidence from randomised controlled trials and real-world data","volume":"11","author":"Efthimiou","year":"2024","journal-title":"Lancet Psychiatry"},{"issue":"8","key":"10.1016\/j.schres.2024.02.035_bb0055","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s40263-017-0448-6","article-title":"Clozapine-induced gastrointestinal Hypomotility: a 22-year bi-National Pharmacovigilance Study of serious or fatal \u2018Slow Gut\u2019 reactions, and comparison with international drug safety advice","volume":"31","author":"Every-Palmer","year":"2017","journal-title":"CNS Drugs"},{"key":"10.1016\/j.schres.2024.02.035_bb0060","series-title":"Expert opinion on (pharmacotherapy)","article-title":"Parkinson\u2019s disease psychosis management: an evidence based, experience informed, pragmatic approach","author":"Friedman","year":"2024"},{"issue":"6","key":"10.1016\/j.schres.2024.02.035_bb0065","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/YIC.0000000000000188","article-title":"Patient attitudes to clozapine initiation","volume":"32","author":"Gee","year":"2017","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2024.02.035_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.scog.2020.100172","article-title":"Neurocognitive variability in schizophrenia spectrum disorders: relationship to real-world functioning","volume":"20","author":"Helldin","year":"2020","journal-title":"Schizophrenia research. Cognition"},{"issue":"15","key":"10.1016\/j.schres.2024.02.035_bb0075","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1017\/S0033291719002344","article-title":"Depressive psychopathology in first-episode schizophrenia spectrum disorders: a systematic review, meta-analysis and meta-regression","volume":"49","author":"Herniman","year":"2019","journal-title":"Psychol. Med."},{"key":"10.1016\/j.schres.2024.02.035_bb0080","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.2147\/NDT.S46108","article-title":"An open-label study of algorithm-based treatment versus treatment-as-usual for patients with schizophrenia","volume":"9","author":"Hirano","year":"2013","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.schres.2024.02.035_bb0085","doi-asserted-by":"crossref","first-page":"s120","DOI":"10.1192\/bjp.187.48.s120","article-title":"International clinical practice guidelines for early psychosis","volume":"48","author":"International Early Psychosis Association Writing Group","year":"2005","journal-title":"Brit. J. Psychiat. Aug."},{"issue":"1","key":"10.1016\/j.schres.2024.02.035_bb0090","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41537-023-00423-3","article-title":"Non-prescribing of clozapine for outpatients with schizophrenia in real-world settings: the clinicians\u2019 perspectives","volume":"9","author":"Jakobsen","year":"2023","journal-title":"Schizophrenia"},{"issue":"10","key":"10.1016\/j.schres.2024.02.035_bb0095","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S2215-0366(18)30252-9","article-title":"Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study","volume":"5","author":"Kahn","year":"2018","journal-title":"Lancet Psychiatry"},{"issue":"10","key":"10.1016\/j.schres.2024.02.035_bb0100","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S2215-0366(18)30252-9","article-title":"Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study","volume":"5","author":"Kahn","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.schres.2024.02.035_bb0105","doi-asserted-by":"crossref","DOI":"10.1177\/20451253221094435","article-title":"Clozapine blood level assessment using a point-of-care device: feasibility and reliability","volume":"12","author":"Kamhi-Nesher","year":"2022","journal-title":"Therap. Adv. Psychopharmacol."},{"issue":"9","key":"10.1016\/j.schres.2024.02.035_bb0110","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Arch. Gen. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2024.02.035_bb0115","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.18com12123","article-title":"Clinical guidance on the identification and Management of Treatment-Resistant Schizophrenia","volume":"80","author":"Kane","year":"2019","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2024.02.035_bb0120","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-013881","article-title":"Pharmacological guidelines for schizophrenia: a systematic review and comparison of recommendations for the first episode","volume":"7","author":"Keating","year":"2017","journal-title":"BMJ Open"},{"issue":"4","key":"10.1016\/j.schres.2024.02.035_bb0125","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/acps.12700","article-title":"The impact of clozapine on hospital use: a systematic review and meta-analysis","volume":"135","author":"Land","year":"2017","journal-title":"Acta Psychiatr. Scand."},{"issue":"9657","key":"10.1016\/j.schres.2024.02.035_bb0130","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.schres.2024.02.035_bb0135","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/eip.13202","article-title":"Efficacy of long-acting injectable versus oral antipsychotic drugs in early psychosis: a systematic review and meta-analysis","volume":"16","author":"Lian","year":"2022","journal-title":"Early Interv. Psychiatry"},{"issue":"12","key":"10.1016\/j.schres.2024.02.035_bb0140","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.schres.2024.02.035_bb0145","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/schbul\/sbac014","article-title":"Primary nonadherence to antipsychotic treatment among persons with schizophrenia","volume":"48","author":"Lieslehto","year":"2022","journal-title":"Schizophr. Bull."},{"issue":"4","key":"10.1016\/j.schres.2024.02.035_bb0150","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/eip.12501","article-title":"Negative symptoms of psychosis: a life course approach and implications for prevention and treatment","volume":"12","author":"Lyne","year":"2018","journal-title":"Early Interv. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2024.02.035_bb0155","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1176\/ajp.2006.163.4.600","article-title":"Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment","volume":"163","author":"McEvoy","year":"2006","journal-title":"Am. J. Psychiatry"},{"issue":"18","key":"10.1016\/j.schres.2024.02.035_bb0160","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1080\/14656566.2021.1958781","article-title":"Dosing antipsychotics in special populations of patients with schizophrenia: severe psychotic agitation, first psychotic episode and elderly patients","volume":"22","author":"Mouaffak","year":"2021","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.schres.2024.02.035_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2019.112671","article-title":"The effect of clinical practice guidelines on prescribing practice in mental health: a systematic review","volume":"284","author":"Nguyen","year":"2020","journal-title":"Psychiatry Res."},{"issue":"6","key":"10.1016\/j.schres.2024.02.035_bb0170","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1001\/jamapsychiatry.2023.0376","article-title":"International variation in clozapine hematologic monitoring-a call for action","volume":"80","author":"Oloyede","year":"2023","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.schres.2024.02.035_bb0175","article-title":"A brief history of clozapine in China with a look forward","author":"Ruan","year":"2023","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.schres.2024.02.035_bb0180","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1600-0447.1993.tb03335.x","article-title":"Poor neuroleptic response in acutely exacerbated schizophrenic patients","volume":"87","author":"Shalev","year":"1993","journal-title":"Acta Psychiatr. Scand."},{"issue":"5","key":"10.1016\/j.schres.2024.02.035_bb0185","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1192\/bjp.bp.115.177261","article-title":"Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis","volume":"209","author":"Siskind","year":"2016","journal-title":"Brit. J. Psychiat."},{"issue":"11","key":"10.1016\/j.schres.2024.02.035_bb0190","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1177\/0706743717718167","article-title":"Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and Meta-analysis","volume":"62","author":"Siskind","year":"2017","journal-title":"Can. J. Psychiatr."},{"issue":"3","key":"10.1016\/j.schres.2024.02.035_bb0195","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1192\/bjp.2021.61","article-title":"Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis","volume":"220","author":"Siskind","year":"2022","journal-title":"Br. J. Psychiatry J. Ment. Sci."},{"key":"10.1016\/j.schres.2024.02.035_bb0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2022.09.009","article-title":"Clinical predictors of antipsychotic treatment resistance: development and internal validation of a prognostic prediction model by the STRATA-G consortium","volume":"250","author":"Smart","year":"2022","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2024.02.035_bb0205","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Bmj"},{"issue":"5","key":"10.1016\/j.schres.2024.02.035_bb0210","doi-asserted-by":"crossref","DOI":"10.1192\/bjo.2020.89","article-title":"Prevalence of treatment resistance and clozapine use in early intervention services","volume":"6","author":"Stokes","year":"2020","journal-title":"BJPsych open"},{"issue":"1","key":"10.1016\/j.schres.2024.02.035_bb0215","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/oxfordjournals.schbul.a006986","article-title":"The National Institute of Mental Health clinical antipsychotic trials of intervention effectiveness (CATIE) project: schizophrenia trial design and protocol development","volume":"29","author":"Stroup","year":"2003","journal-title":"Schizophr. Bull."},{"issue":"4","key":"10.1016\/j.schres.2024.02.035_bb0220","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1176\/ajp.2006.163.4.611","article-title":"Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic","volume":"163","author":"Stroup","year":"2006","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2024.02.035_bb0225","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1176\/ajp.2007.164.3.415","article-title":"Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study","volume":"164","author":"Stroup","year":"2007","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2024.02.035_bb0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2008.10.011","article-title":"Results of phase 3 of the CATIE schizophrenia trial","volume":"107","author":"Stroup","year":"2009","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.schres.2024.02.035_bb0235","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00213-007-0872-2","article-title":"How effective is it to sequentially switch among olanzapine, quetiapine and risperidone? - a randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting","volume":"195","author":"Suzuki","year":"2007","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.schres.2024.02.035_bb0240","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/eip.12683","article-title":"Delays and barriers to the commencement of clozapine in eligible people with a psychotic disorder: a literature review","volume":"13","author":"Thien","year":"2019","journal-title":"Early Interv. Psychiatry"},{"key":"10.1016\/j.schres.2024.02.035_bb0245","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.schres.2018.02.054","article-title":"Clozapine use in early psychosis","volume":"199","author":"Thien","year":"2018","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.schres.2024.02.035_bb0250","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/schbul\/sby052","article-title":"Clozapine and long-term mortality risk in patients with schizophrenia: a systematic review and Meta-analysis of studies lasting 1.1-12.5 years","volume":"45","author":"Vermeulen","year":"2019","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2024.02.035_bb0255","author":"Wells"},{"issue":"2","key":"10.1016\/j.schres.2024.02.035_bb0260","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1038\/s41380-021-01331-7","article-title":"A multimodal study of a first episode psychosis cohort: potential markers of antipsychotic treatment resistance","volume":"27","author":"Yang","year":"2022","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.schres.2024.02.035_bb0265","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.psychres.2017.01.064","article-title":"The critical treatment window of clozapine in treatment-resistant schizophrenia: secondary analysis of an observational study","volume":"250","author":"Yoshimura","year":"2017","journal-title":"Psychiatry Res."},{"issue":"1","key":"10.1016\/j.schres.2024.02.035_bb0270","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/eip.12442","article-title":"Algorithm-based pharmacotherapy for first-episode schizophrenia involuntarily hospitalized: a retrospective analysis of real-world practice","volume":"13","author":"Yoshimura","year":"2019","journal-title":"Early Interv. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2024.02.035_bb0275","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/eip.12442","article-title":"Algorithm-based pharmacotherapy for first-episode schizophrenia involuntarily hospitalized: a retrospective analysis of real-world practice","volume":"13","author":"Yoshimura","year":"2019","journal-title":"Early Interv. Psychiatry"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092099642400080X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092099642400080X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T10:27:41Z","timestamp":1718101661000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092099642400080X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":55,"alternative-id":["S092099642400080X"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2024.02.035","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Response rates to sequential trials of antipsychotic medications according to algorithms or treatment guidelines in psychotic disorders. A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2024.02.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}